{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T13:44:55Z","timestamp":1769607895245,"version":"3.49.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,1,3]],"date-time":"2019-01-03T00:00:00Z","timestamp":1546473600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s12325-018-0862-2","type":"journal-article","created":{"date-parts":[[2019,1,3]],"date-time":"2019-01-03T12:42:09Z","timestamp":1546519329000},"page":"355-364","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy, Tolerability and Pharmacokinetic Impact of Aprepitant in Sarcoma Patients Receiving Ifosfamide and Doxorubicin Chemotherapy: A Randomized Controlled Trial"],"prefix":"10.1007","volume":"36","author":[{"given":"Jie","family":"Xiong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guifang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengli","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,3]]},"reference":[{"key":"862_CR1","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s10195-013-0265-8","volume":"15","author":"JS Hwang","year":"2014","unstructured":"Hwang JS, Mehta AD, Yoon RS, Beebe KS. From amputation to limb salvage reconstruction: evolution and role of the endoprosthesis in musculoskeletal oncology. J Orthop Traumatol. 2014;15:81\u20136.","journal-title":"J Orthop Traumatol"},{"key":"862_CR2","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/00000421-199806000-00025","volume":"21","author":"SR Patel","year":"1998","unstructured":"Patel SR, Vadhan-Raj S, Burgess MA, et al. Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol. 1998;21:317\u201321.","journal-title":"Am J Clin Oncol"},{"key":"862_CR3","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S1470-2045(14)70063-4","volume":"15","author":"I Judson","year":"2014","unstructured":"Judson I, Verweij J, Gelderblom H, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomized controlled phase 3 trial. Lancet Oncol. 2014;15:415\u201323.","journal-title":"Lancet Oncol"},{"key":"862_CR4","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1200\/JOP.2015.009944","volume":"12","author":"MJ Wagner","year":"2016","unstructured":"Wagner MJ, Livingston JA, Patel SR, Benjamin RS. Chemotherapy for bone sarcoma in adults. J Oncol Pract. 2016;12:208\u201316.","journal-title":"J Oncol Pract"},{"key":"862_CR5","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s002800000219","volume":"47","author":"L Serrone","year":"2001","unstructured":"Serrone L, Zeuli M, Gamucci T, Nardi M, Cognetti F. A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule. Cancer Chemother Pharmacol. 2001;47:206\u201310.","journal-title":"Cancer Chemother Pharmacol"},{"key":"862_CR6","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/S0028-3908(96)00020-2","volume":"35","author":"FD Tattersall","year":"1996","unstructured":"Tattersall FD, Rycroft W, Francis B, et al. Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets. Neuropharmacology. 1996;35:1121\u20139.","journal-title":"Neuropharmacology"},{"key":"862_CR7","doi-asserted-by":"publisher","first-page":"4112","DOI":"10.1200\/JCO.2003.01.095","volume":"21","author":"PJ Hesketh","year":"2003","unstructured":"Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin\u2014the Aprepitant Protocol 052 Study Group. J Clin Oncol. 2003;21:4112\u20139.","journal-title":"J Clin Oncol"},{"key":"862_CR8","doi-asserted-by":"publisher","first-page":"3090","DOI":"10.1002\/cncr.11433","volume":"97","author":"S Poli-Bigelli","year":"2003","unstructured":"Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer. 2003;97:3090\u20138.","journal-title":"Cancer"},{"key":"862_CR9","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1093\/annonc\/mdl019","volume":"17","author":"HJ Schmoll","year":"2006","unstructured":"Schmoll HJ, Aapro MS, Poli-Bigelli S, et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol. 2006;17:1000\u20136.","journal-title":"Ann Oncol"},{"key":"862_CR10","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.1200\/JCO.2005.09.050","volume":"23","author":"DG Warr","year":"2005","unstructured":"Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol. 2005;23:2822\u201330.","journal-title":"J Clin Oncol"},{"key":"862_CR11","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1124\/dmd.104.000216","volume":"32","author":"RI Sanchez","year":"2004","unstructured":"Sanchez RI, Wang RW, Newton DJ, et al. Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metab Dispos. 2004;32:1287\u201392.","journal-title":"Drug Metab Dispos"},{"key":"862_CR12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2174\/138920006774832587","volume":"7","author":"K Fujita","year":"2006","unstructured":"Fujita K. Cytochrome P450 and anticancer drugs. Curr Drug Metab. 2006;7:23\u201337.","journal-title":"Curr Drug Metab"},{"key":"862_CR13","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/S0009-9236(03)00123-1","volume":"74","author":"AK Majumdar","year":"2003","unstructured":"Majumdar AK, McCrea JB, Panebianco DL, et al. Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe. Clin Pharmacol Ther. 2003;74:150\u20136.","journal-title":"Clin Pharmacol Ther"},{"key":"862_CR14","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1177\/0091270003262950","volume":"44","author":"CR Shadle","year":"2004","unstructured":"Shadle CR, Lee Y, Majumdar AK, et al. Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity. J Clin Pharmacol. 2004;44:215\u201323.","journal-title":"J Clin Pharmacol"},{"key":"862_CR15","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1093\/annonc\/mdm104","volume":"18","author":"JP Durand","year":"2007","unstructured":"Durand JP, Gourmel B, Mir O, Goldwasser F. Antiemetic neurokinin-1 antagonist aprepitant and ifosfamide-induced encephalopathy. Ann Oncol. 2007;18:808\u20139.","journal-title":"Ann Oncol"},{"key":"862_CR16","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.2146\/ajhp080069","volume":"65","author":"A Jarkowski 3rd","year":"2008","unstructured":"Jarkowski A 3rd. Possible contribution of aprepitant to ifosfamide-induced neurotoxicity. Am J Health Syst Pharm. 2008;65:2229\u201331.","journal-title":"Am J Health Syst Pharm"},{"key":"862_CR17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0009-9236(03)00066-3","volume":"74","author":"JB McCrea","year":"2003","unstructured":"McCrea JB, Majumdar AK, Goldberg MR, et al. Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther. 2003;74:17\u201324.","journal-title":"Clin Pharmacol Ther"},{"key":"862_CR18","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1179\/joc.1999.11.1.69","volume":"11","author":"C Zolezzi","year":"1999","unstructured":"Zolezzi C, Ferrari S, Bacci G, Fasano MC, Sormani G, Pizzoferrato A. Determination of ifosfamide by HPLC using on-line sample preparation. J Chemother. 1999;11:69\u201373.","journal-title":"J Chemother"},{"key":"862_CR19","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1200\/JCO.2001.19.6.1759","volume":"19","author":"D Campos","year":"2001","unstructured":"Campos D, Pereira JR, Reinhardt R, et al. Prevention of cisplatin induced emesis by the oral neurokinin-1 antagonist, aprepitant, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol. 2001;19:1759\u201367.","journal-title":"J Clin Oncol"},{"key":"862_CR20","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1056\/NEJM199901213400304","volume":"340","author":"R Navari","year":"1999","unstructured":"Navari R, Reinhardt R, Gralla RJ, et al. Reduction of cisplatininduced emesis by a selective neurokinin-1 receptor antagonist. N Engl J Med. 1999;340:190\u20135.","journal-title":"N Engl J Med"},{"key":"862_CR21","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/S0959-8049(00)00416-0","volume":"37","author":"V Cocquyt","year":"2001","unstructured":"Cocquyt V, Van Belle S, Reinhardt R, et al. Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. Eur J Cancer. 2001;37:835\u201342.","journal-title":"Eur J Cancer"},{"key":"862_CR22","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.1002\/cncr.10516","volume":"94","author":"S Belle Van","year":"2002","unstructured":"Van Belle S, Lichinitser MR, Navari R, et al. Prevention of cisplatin induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869: a randomized controlled trial. Cancer. 2002;94:3032\u201341.","journal-title":"Cancer"},{"key":"862_CR23","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s00280-006-0359-6","volume":"59","author":"WJ Loos","year":"2007","unstructured":"Loos WJ, de Wit R, Freedman SJ, et al. Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients. Cancer Chemother Pharmacol. 2007;59:407\u201312.","journal-title":"Cancer Chemother Pharmacol"},{"key":"862_CR24","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s00280-004-0946-3","volume":"55","author":"P Nygren","year":"2005","unstructured":"Nygren P, Hande K, Petty KJ, et al. Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients. Cancer Chemother Pharmacol. 2005;55:609\u201316.","journal-title":"Cancer Chemother Pharmacol"},{"key":"862_CR25","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/j.1472-8206.2005.00367.x","volume":"19","author":"D Beulz-Rich\u00e9","year":"2005","unstructured":"Beulz-Rich\u00e9 D, Grud\u00e9 P, Puozzo C, et al. Characterization of human cytochrome P450 isoenzymes involved in the metabolism of vinorelbine. Fundam Clin Pharmacol. 2005;19:545\u201353.","journal-title":"Fundam Clin Pharmacol"},{"key":"862_CR26","first-page":"1296","volume":"56","author":"F Marre","year":"1996","unstructured":"Marre F, Sanderink GJ, de Sousa G, Gaillard C, Martinet M, Rahmani R. Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res. 1996;56:1296\u2013302.","journal-title":"Cancer Res"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-018-0862-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-018-0862-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-018-0862-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T00:26:00Z","timestamp":1578011160000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-018-0862-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,3]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["862"],"URL":"https:\/\/doi.org\/10.1007\/s12325-018-0862-2","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,3]]},"assertion":[{"value":"6 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}